Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Jul;16(1):17–25. doi: 10.1111/j.1365-2125.1983.tb02138.x

A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.

T Ishizaki, Y Oyama, T Suganuma, T Sasaki, H Nakaya, T Shibuya, T Sato
PMCID: PMC1427944  PMID: 6349668

Abstract

The relationship between the oral dosage and plasma concentration of the long-acting cardioselective beta-adrenoceptor blocker atenolol and the antihypertensive response to the the degree of beta-adrenoceptor blockade and change in plasma renin activity (PRA) was evaluated in patients with mild-to-moderate essential hypertension in a double-blind, randomized, between-patient, dose-ranging (25, 50 or 100 mg once daily for 4 weeks) study. The optimum, or minimum, daily dose of atenolol to treat patients with mild-to-moderate hypertension was not clearly identified in this study. A between-treatment comparison did not demonstrate that all blood pressure falls were always less in the 25 mg group than in the other two groups. Calculation of beta-error or the power for the negative results between doses suggested that a large sample size is required to draw a conclusion that no dose-antihypertensive relationship of atenolol exists in the treatment of mild-to-moderate hypertension. A relatively flat plasma concentration-antihypertensive response relationship was observed. Steady-state plasma concentrations of atenolol were dose-related and renal drug clearance was well correlated with individual creatinine clearance. beta-adrenoceptor blockade was better correlated with plasma atenolol concentration. Correlations which were less strong were between plasma drug concentration and change in various blood pressures and between blood pressure falls and beta-adrenoceptor blockade. There was no relationship between the fall in blood pressure and change in PRA. Atenolol appeared to suppress PRA in an all-or-none fashion.

Full text

PDF
17

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anavekar S. N., Louis W. J., Morgan T. O., Doyle A. E., Johnston C. I. The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol. 1975 May-Jun;2(3):203–212. doi: 10.1111/j.1440-1681.1975.tb03026.x. [DOI] [PubMed] [Google Scholar]
  2. Bengtsson C., Johnsson G., Regårdh C. G. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975 Apr;17(4):400–408. doi: 10.1002/cpt1975174400. [DOI] [PubMed] [Google Scholar]
  3. Bühler F. R., Burkart F., Lütold B. E., Küng M., Marbet G., Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975 Oct 31;36(5):653–669. doi: 10.1016/0002-9149(75)90168-x. [DOI] [PubMed] [Google Scholar]
  4. Collste P., Haglund K., Frisk-Holmberg M., Orme M. L., Rawlins M. D., Ostman J. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity. Eur J Clin Pharmacol. 1976 Jun 15;10(2):89–95. doi: 10.1007/BF00609465. [DOI] [PubMed] [Google Scholar]
  5. Cruickshank J. M., Neil-Dwyer G., Cameron M. M., McAinsh J. beta-Adrenoreceptor-blocking agents and the blood-brain barrier. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):453s–455s. doi: 10.1042/cs059453s. [DOI] [PubMed] [Google Scholar]
  6. Cruickshank J. M. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980 Aug;100(2):160–178. doi: 10.1016/0002-8703(80)90112-x. [DOI] [PubMed] [Google Scholar]
  7. Distler A., Keim H. J., Cordes U., Philipp T., Wolff H. P. Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension. Am J Med. 1978 Mar;64(3):446–451. doi: 10.1016/0002-9343(78)90231-0. [DOI] [PubMed] [Google Scholar]
  8. Douglas-Jones A. P., Baber N. S., Lee A. Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding study. Eur J Clin Pharmacol. 1978 Nov 27;14(3):163–166. doi: 10.1007/BF02089954. [DOI] [PubMed] [Google Scholar]
  9. Douglas-Jones A. P., Cruickshank J. M. Once-daily dosing with Atenolol in patients with mild or moderate hypertension. Br Med J. 1976 Apr 24;1(6016):990–991. doi: 10.1136/bmj.1.6016.990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Esler M., Zweifler A., Randall O., DeQuattro V. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol. Clin Pharmacol Ther. 1977 Sep;22(3):299–308. doi: 10.1002/cpt1977223299. [DOI] [PubMed] [Google Scholar]
  11. Feinstein A. R. Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size. Clin Pharmacol Ther. 1975 Oct;18(4):491–505. doi: 10.1002/cpt1975184491. [DOI] [PubMed] [Google Scholar]
  12. Freiman J. A., Chalmers T. C., Smith H., Jr, Kuebler R. R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978 Sep 28;299(13):690–694. doi: 10.1056/NEJM197809282991304. [DOI] [PubMed] [Google Scholar]
  13. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  14. Hollifield J. W., Sherman K., Zwagg R. V., Shand D. G. Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. N Engl J Med. 1976 Jul 8;295(2):68–73. doi: 10.1056/NEJM197607082950203. [DOI] [PubMed] [Google Scholar]
  15. Ishizaki T., Hirayama H., Tawara K., Nakaya H., Sato M., Sato K. Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug. J Pharmacol Exp Ther. 1980 Jan;212(1):173–181. [PubMed] [Google Scholar]
  16. Ishizaki T., Tawara K. Comparison of disposition and effect of timolol and propranolol on exercise tachycardia. Eur J Clin Pharmacol. 1978 Nov 9;14(1):7–14. doi: 10.1007/BF00560252. [DOI] [PubMed] [Google Scholar]
  17. Ishizaki T., Tawara K., Oyama Y., Nakaya H. Clinical pharmacologic observations on timolol. II. Antihypertensive effect and kinetic disposition on twice-daily dosing in patients with mild or moderate hypertension. J Clin Pharmacol. 1978 Nov-Dec;18(11-12):519–529. doi: 10.1002/j.1552-4604.1978.tb01581.x. [DOI] [PubMed] [Google Scholar]
  18. Jeffers T. A., Webster J., Petrie J. C., Barker N. P. Atenolol once-daily in hypertension. Br J Clin Pharmacol. 1977 Oct;4(5):523–527. doi: 10.1111/j.1365-2125.1977.tb00780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Krediet R. T., Dunning A. J., Offerhaus L. Relationship of propranolol pharmacokinetics to antihypertensive effect and beta-adrenergic blockade in the treatment of hypertension. Eur J Clin Pharmacol. 1980 Nov;18(5):391–394. doi: 10.1007/BF00636790. [DOI] [PubMed] [Google Scholar]
  20. Lehtonen A., Kanto J., Kleimola T. Plasma concentrations of propranolol in patients with essential hypertension. Eur J Clin Pharmacol. 1977 Mar 11;11(3):155–157. doi: 10.1007/BF00606403. [DOI] [PubMed] [Google Scholar]
  21. Marshall A. J., Barritt D. W., Harry J. D. Dose response and frequency of administration of atenolol in essential hypertension--once daily treatment with beta-blockade. Postgrad Med J. 1977;53 (Suppl 3):168–172. [PubMed] [Google Scholar]
  22. Marshall A. J., Barritt D. W., Heaton S., Harry J. D. Dose response for blood pressure and degree of cardiac beta-blockade with atenolol. Postgrad Med J. 1979 Sep;55(646):537–540. doi: 10.1136/pgmj.55.646.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McDevitt D. G. The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol. 1977 Aug;4(4):413–425. doi: 10.1111/j.1365-2125.1977.tb00756.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Morgan T. O., Roberts R., Carney S. L., Louis W. J., Doyle A. E. Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol. 1975 Apr;2(2):159–164. doi: 10.1111/j.1365-2125.1975.tb01571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Myers M. G., Lewis G. R., Steiner J., Dollery C. T. Atenolol in essential hypertension. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):502–507. doi: 10.1002/cpt1976195part1502. [DOI] [PubMed] [Google Scholar]
  26. Myers M. G., Lewis P. J., Reid J. L., Dollery C. T. Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. J Pharmacol Exp Ther. 1975 Feb;192(2):327–335. [PubMed] [Google Scholar]
  27. Myers M. G., Thiessen J. J. Metoprolol kinetics and dose response in hypertensive patients. Clin Pharmacol Ther. 1980 Jun;27(6):756–762. doi: 10.1038/clpt.1980.106. [DOI] [PubMed] [Google Scholar]
  28. Neil-Dwyer G., Bartlett J., McAinsh J., Cruickshank J. M. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol. 1981 Jun;11(6):549–553. doi: 10.1111/j.1365-2125.1981.tb01169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Petrie J. C., Jeffers T. A., Galloway D. B., Webster J. Clinical studies with atenolol in hypertension. Postgrad Med J. 1977;53 (Suppl 3):173–175. [PubMed] [Google Scholar]
  30. Scales B., Copsey P. B. The gas chromatographic determination of atenolol in biological samples. J Pharm Pharmacol. 1975 Jun;27(6):430–433. doi: 10.1111/j.2042-7158.1975.tb09473.x. [DOI] [PubMed] [Google Scholar]
  31. Serlin M. J., Orme M. L., Baber N. S., Sibeon R. G., Laws E., Breckenridge A. Propranolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther. 1980 May;27(5):586–592. doi: 10.1038/clpt.1980.83. [DOI] [PubMed] [Google Scholar]
  32. Wilcox R. G. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. Br Med J. 1978 Aug 5;2(6134):383–385. doi: 10.1136/bmj.2.6134.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. van Zwieten P. A., Timmermans P. B. Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol. J Cardiovasc Pharmacol. 1979 Jan-Feb;1(1):85–96. doi: 10.1097/00005344-197901000-00009. [DOI] [PubMed] [Google Scholar]
  34. von Bahr C., Collste P., Frisk-Holmberg M., Haglund K., Jorfelt L., Orme M., Ostman J., Sjoqvist F. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension. Clin Pharmacol Ther. 1976 Aug;20(2):130–137. doi: 10.1002/cpt1976202130. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES